Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

Completed · Phase 1/Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients who have progressive or recurrent malignant glioma.

Key facts

Study ID

NCT00003616

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

1998-10-22

Expected to finish

2005-12-20

Last updated by the study team

2018-06-27

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Simmons Cancer Center - Dallas — Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.